HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

NVCR

NovoCure Limited

Healthcare — Medical Devices

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Buy 2.0 / 5 7 analysts
$15.92
$-0.03 (-0.19%)
Target: $27.14 (70.5%)

Price History

52-Week Range
Sign in to add NVCR to a watchlist or set price alerts.

Fundamentals

Market Cap$1.73B
P/E Ratio (TTM)-
Forward P/E-16.22
EPS (TTM)$-1.27
Dividend Yield-
Profit Margin-21.25%
Revenue Growth15.60%
ROE-43.22%
Debt/Equity69.04
Recommendation Buy 2.0
Analyst Target$27.14
Analysts7
Next Earnings Oct 29, 2026 BMO
Indexes -

Technical Indicators

RSI (14)44.8
Beta0.94
SMA 20$16.49
SMA 40$16.37
52-Week High$21.45
52-Week Low$9.82
50-Day Avg$16.53
200-Day Avg$13.79
Avg Volume$1.79M
Volume$1.19M

Performance Analysis

NEUTRAL

NVCR presents a mixed picture with both positive and negative indicators.

~ Trading at 52% of its 52-week range.
~ RSI at 44.8 is in neutral territory.
~ Price dropped below the 50-day average but remains above the 200-day — possible short-term weakness.
~ Modest revenue growth of 15.6% year-over-year.
- Operating at a loss with -21.2% margin.
+ Wall Street consensus is "Buy" from 7 analysts.
+ Average analyst target of $27.14 implies 70.5% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Aug 01, 2026 05:07 UTC

Back to Screener Export Report